title: Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53.
abstract: MicroRNAs (miRNAs) regulate the expression of multiple proteins in a dose-dependent manner. We hypothesized that increased expression of miRNAs encoded on chromosome 21 (chr 21) contribute to the leukemogenic function of trisomy 21. The levels of chr 21 miRNAs were quantified by qRT-PCR in four types of childhood acute lymphoblastic leukemia (ALL) characterized by either numerical (trisomy or tetrasomy) or structural abnormalities of chr 21. Suprisingly, high expression of the hsa-mir-125b-2 cluster, consisting of three miRNAs, was identified in leukemias with the structural ETV6/RUNX1 abnormality and not in ALLs with trisomy 21. Manipulation of ETV6/RUNX1 expression and chromatin immunoprecipitation studies showed that the high expression of the miRNA cluster is an event independent of the ETV6/RUNX1 fusion protein. Overexpression of hsa-mir-125b-2 conferred a survival advantage to Ba/F3 cells after IL-3 withdrawal or a broad spectrum of apoptotic stimuli through inhibition of caspase 3 activation. Conversely, knockdown of the endogenous miR-125b in the ETV6/RUNX1 leukemia cell line REH increased apoptosis after Doxorubicin and Staurosporine treatments. P53 protein levels were not altered by miR-125b. Together, these results suggest that the expression of hsa-mir-125b-2 in ETV6/RUNX1 ALL provides survival advantage to growth inhibitory signals in a p53-independent manner.
authors.affiliation: Section of Functional Genomics and Leukemia Research, Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel-Hashomer, Israel.
authors.forename: N
authors.initials: N
authors.lastname: Gefen
authors.forename: V
authors.initials: V
authors.lastname: Binder
authors.forename: M
authors.initials: M
authors.lastname: Zaliova
authors.forename: Y
authors.initials: Y
authors.lastname: Linka
authors.forename: M
authors.initials: M
authors.lastname: Morrow
authors.forename: A
authors.initials: A
authors.lastname: Novosel
authors.forename: L
authors.initials: L
authors.lastname: Edry
authors.forename: L
authors.initials: L
authors.lastname: Hertzberg
authors.forename: N
authors.initials: N
authors.lastname: Shomron
authors.forename: O
authors.initials: O
authors.lastname: Williams
authors.forename: J
authors.initials: J
authors.lastname: Trka
authors.forename: A
authors.initials: A
authors.lastname: Borkhardt
authors.forename: S
authors.initials: S
authors.lastname: Izraeli
mesh_terms: D050676:Core Binding Factor Alpha 2 Subunit / Q000032:analysis / Q000502:physiology*; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000032:analysis; D006801:Humans; D007377:Interleukin-3 / Q000502:physiology; D035683:MicroRNAs / Q000032:analysis*; D015514:Oncogene Proteins, Fusion / Q000032:analysis / Q000502:physiology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000502:physiology*; D000097764:ETS Translocation Variant 6 Protein
chemical_list: D050676:Core Binding Factor Alpha 2 Subunit; D050759:Cyclin-Dependent Kinase Inhibitor p21; D007377:Interleukin-3; D035683:MicroRNAs; D015514:Oncogene Proteins, Fusion; D016159:Tumor Suppressor Protein p53; C493956:CDKN1A protein, human; C531888:MIRN125 microRNA, human; C102421:TEL-AML1 fusion protein; D000097764:ETS Translocation Variant 6 Protein